CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 6,967 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $52.58, for a total value of $366,324.86. Following the completion of the sale, the chief executive officer directly owned 226,106 shares of the company’s stock, valued at approximately $11,888,653.48. This represents a 2.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $51.75, for a total value of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00.

CRISPR Therapeutics Price Performance

Shares of CRSP stock traded down $1.18 on Friday, hitting $53.46. 1,297,432 shares of the stock traded hands, compared to its average volume of 1,744,686. The company’s fifty day moving average is $53.90 and its 200 day moving average is $57.27. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The company has a market capitalization of $5.13 billion, a PE ratio of -8.20 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The business’s revenue for the quarter was down 97.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.01) EPS. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Institutional Trading of CRISPR Therapeutics

A number of institutional investors have recently made changes to their positions in CRSP. ARK Investment Management LLC increased its stake in shares of CRISPR Therapeutics by 7.5% during the fourth quarter. ARK Investment Management LLC now owns 10,522,057 shares of the company’s stock valued at $551,777,000 after acquiring an additional 735,084 shares during the period. Orbis Allan Gray Ltd boosted its stake in CRISPR Therapeutics by 19.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 5,950,145 shares of the company’s stock valued at $312,026,000 after purchasing an additional 968,060 shares in the last quarter. Capital International Investors increased its position in shares of CRISPR Therapeutics by 4.3% during the 4th quarter. Capital International Investors now owns 5,892,745 shares of the company’s stock valued at $309,016,000 after purchasing an additional 243,487 shares during the period. State Street Corp raised its stake in shares of CRISPR Therapeutics by 35.6% in the 2nd quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after buying an additional 859,334 shares in the last quarter. Finally, GSK plc acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at $168,890,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on CRSP. Chardan Capital lifted their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a research note on Saturday, February 14th. Robert W. Baird reduced their price objective on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Morgan Stanley restated an “underweight” rating and set a $33.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday. Royal Bank Of Canada raised their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 11th. Finally, Evercore reissued an “outperform” rating and set a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. Ten equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $64.24.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.